Vasamed公司推出非创伤性血液动力学诊断系统

 
一种新型阻抗心动图（ICG）非创伤性血液动力学诊断系统，被设计用于评估心血管功能。

这种AcQtrac ICG系统提供了快速可靠的信息，帮助医生评估和治疗晚期心衰、高血压和其他心血管疾病。根据Vasamed公司的说法，该系统的非创伤性监测设备比其他同类的非创伤性产品更加安全、有效而且性价比更好。正是该公司研制了这套系统。

“这套AcQtrac ICG在其同类产品是独一无二的，它能够提供心脏的波形‘图像’，可以作为诊断的辅助资料，有助于指导药物治疗，” Paulita LaPlante如此评论说，她是Vasamed (Minneapolis, MN, USA)公司的总裁，该公司研制开发了这套AcQtrac系统。“作为一个女人，我特别关注每年有女性死于心血管疾病的比乳腺癌还要多。事实上在美国死于心脏疾病和脑卒中疾病的女性要比男性还多。”

研究现实对女性心血管疾病的诊断更加困难。Vasamed致力于提供医疗策略和解决方案，改善女性患者以及其他患者的预后。该公司预期将他们的新诊断工具推向心衰诊所、私人心脏病诊室、重症监护室、急诊科、儿科心脏病专家。

Hemodynamic Diagnostic System
 
A new impedance cardiography (ICG) noninvasive hemodynamic diagnostic system is designed for the assessment of cardiovascular functioning.

The AcQtrac ICG system provides rapid, reliable information enabling doctors to assess and treat advanced heart failure, hypertension, and other cardiovascular diseases. The system’s noninvasive monitors are safer, more efficient, and more cost-effective to use than it noninvasive counterparts, according to Vasamed, which developed the system.

“The AcQtrac ICG is unique in its class since it provides a waveform ‘image’ of the heart that serves as a diagnostic aid and helpful tool in guiding drug therapy management,” said Paulita LaPlante, president of Vasamed (Minneapolis, MN, USA), which developed the AcQtrac system. “As a woman, I am particularly focused on the tragedy that more women die of cardiovascular disease annually than they do from breast cancer. In fact more women than men in the United States die of heart disease and stroke.”

Research has shown that it is more difficult to diagnose cardiovascular disease in women. Vasamed intends to offer medical strategies and solutions that improve outcomes for women as well as all other patients. The company anticipates marketing its new diagnostic tool to heart-failure clinics, private cardiology offices, critical care monitoring units, emergency departments, and pediatric cardiology specialists.